“As world leaders in gene and cell therapy development, our teams at Penn Medicine are committed to ensuring that patients can count on us to provide them with cutting-edge care. Porter, M.D., director of Cell Therapy and Transplantation in Penn Medicine’s Abramson Cancer Center and the Jodi Fisher Horowitz professor in Leukemia Care Excellence in the Perelman School of Medicine. “We are excited to collaborate with Independence in this important, emerging area of medicine,” said David L. As pioneers of these approaches, they also have staff who are experts in the protocols established by manufacturers to ensure optimal safety and the best possible outcomes when administering the therapies to patients. Both have played pivotal roles in the development and clinical trials of first-in-the-nation gene-based therapies, which have paved the way for their approvals by the U.S. The providers in Independence’s Advanced Network for Gene-Based Therapeutics include Penn Medicine and Children’s Hospital of Philadelphia (CHOP). That’s why we’re committed to making sure our members have continued access to these important treatment options. “Gene-based therapies, although expensive, are often one-dose treatments and have so much potential to improve a person’s quality of life. “We’re proud to launch this new network as part of our comprehensive strategy to manage specialty drugs,” said Rodrigo Cerdá, M.D, senior vice president of Health Services and chief medical officer at Independence. These treatments provide fresh hope for patients with inherited rare genetic conditions, including a form of blindness and severe neurological and blood diseases. The new network is designed to help members access potentially life-changing gene-based therapies from best-in-class health care providers that have demonstrated an ability to exceed quality, safety, and value benchmarks in administering gene-based therapies. Independence Blue Cross (Independence) today announced the launch of its Advanced Network for Gene-Based Therapeutics, which will be effective March 1, 2023. Network includes gene therapy leaders Penn Medicine and Children’s Hospital of Philadelphia
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |